[1] LIU Y, SU L, JIANG SJ,et al. Risk factors for mortality from Pneumocystis carinii pneumonia (PCP) in non-HIV patients:a meta-analysis[J]. Oncotarget,2017,8(35):59729-59739. [2] CORDONNIER C,CESARO S,MASCHMEYER G,et al. Pneumocystis jirovecii pneumonia:still a concern in patients with haematological malignancies and stem cell transplant recipients[J].J Antimicrob Chemother,2016,71(9):2379-2385. [3] TORRES H A,CHEMALY R F,STOREY R, et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients[J]. Eur J Clin Microbiol Infect Dis, 2006,25(6):382-388. [4] MCKINNELL J A,CANNELLA A P,KUNZ D F,et al. Pneumocystis pneumonia in hospitalized patients:a detailed examination of symptoms, management, and outcomes in human immunodeficiency virus (HIV)-infected and HIV-uninfected persons[J]. Transpl Infect Dis,2012,14(5):510-518. [5] ROBERT-GANGNEUX F,BELAZ S,REVEST M, et al. Diagnosis of Pneumocystis jirovecii pneumonia in immunocompromised patients by real-time PCR:a 4-year prospective study[J]. J Clin Microbiol,2014,52(9):3370-3376. [6] LAHMER T,DA COSTA C P,HELD J,et al. Usefulness of 1,3 beta-d-glucan detection in non-HIV immunocompromised mechanical ventilated critically Ill patients with ARDS and suspected Pneumocystis jirovecii pneumonia[J]. Mycopathologia,2017,182(7):701-708. [7] ROBLOT F,LE MOAL G,KAUFFMANN-LACROIX C, et al. Pneumocystis jirovecii pneumonia in HIV-negative patients:a prospective study with focus on immunosuppressive drugs and markers of immune impairment[J]. Scand J Infect Dis,2014,46(3):210-214. [8] MESSIAEN P E,CUYX S,DEJAGERE T,et al. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients:A systematic review[J]. Transpl Infect Dis,2017,19(2):e12651. [9] BIENVENU A L,TRAORE K,PLEKHANOVA I, et al. Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients[J]. Int J Infect Dis, 2016, 46:11-17. [10] LI MC, LEE NY, LEE CC, et al.Pneumocystis jiroveci pneumonia in immunocompromised patients:delayed diagnosis and poor outcomes in non-HIV-infected individuals[J]. J Microbiol Immunol Infect,2014,47(1):42-47. [11] MASCHMEYER G, HELWEY-LARSEN J,PAGANO L, et al. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients[J]. J Antimicrob Chemother,2016,71(9):2405-2413. [12] AMADO-RODRÍGUEZ L, BERNAL T, López-Alonso I, et al. Impact of initial ventilatory strategy in hematological patients with acute respiratory failure:A systematic review and Meta-analysis[J]. Crit Care Med, 2016,44(7):1406-1413. [13] LEMIALE V,DEBRUMETZ A,DELANNOY A, et al. Adjunctive steroid in HIV-negative patients with severe pneumocystis pneumonia[J]. Respir Res, 2013, 14:87. [14] GREEN H,PAUL M,VIDAL L, et al. Prophylaxis of pneumocystis pneumonia in immunocompromised non-HIV-infected patients:systematic review and meta-analysis of randomized controlled trials[J]. Mayo Clin Proc, 2007, 82(9):1052-1059. [15] MAERTENS J,CESARO S,MASCHMEYER G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients[J]. J Antimicrob Chemother,2016, 71(9):2397-2404. |